SCHEMBL5084408

SCHEMBL5084408

CCCCCC/C=C(\N)C(N)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.55
FAAH O00519 4/20 0.53
SOAT1 P35610 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C19 P33261 2/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
TP53 P04637 1/20 0.53
CYP3A4 P08684 1/20 0.53
KDM4E B2RXH2 2/20 0.48
CNR1 P21554 1/20 0.46
TSHR P16473 1/20 0.44
TERT O14746 3/20 0.44
MAPT P10636 2/20 0.44
BLM P54132 2/20 0.44
HSD17B10 Q99714 2/20 0.44
FABP4 P15090 2/20 0.44
GMNN O75496 1/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19980211 0.91 EP300 (0.43) EP300FAAHSOAT1CYP1A2CYP2C19
SCHEMBL29134998 0.91 EP300 (0.43) EP300FAAHSOAT1CYP1A2CYP2C19
SCHEMBL27721505 0.85 EP300 (0.64) EP300FAAHSOAT1CYP1A2CYP2C19
SCHEMBL27822155 0.85 EP300 (0.64) EP300FAAHSOAT1CYP1A2CYP2C19
SCHEMBL1886380 0.85 EP300 (0.64) EP300FAAHSOAT1CYP1A2CYP2C19
SCHEMBL27841412 0.85 EP300 (0.64) EP300FAAHSOAT1CYP1A2CYP2C19
SCHEMBL6668610 0.85 EP300 (0.64) EP300FAAHSOAT1CYP1A2CYP2C19
SCHEMBL29702823 0.85 EP300 (0.64) EP300FAAHSOAT1CYP1A2CYP2C19
SCHEMBL27357142 0.85 EP300 (0.64) EP300FAAHSOAT1CYP1A2CYP2C19
SCHEMBL6669081 0.85 EP300 (0.64) EP300FAAHSOAT1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028671-A1 Sequencing by Structure Assembly HARVARD COLLEGE (US) 2026-01-29 US disclosed
US-20250369043-A1 LINKERS AND METHODS FOR OPTICAL DETECTION AND SEQUENCING ULTIMA GENOMICS INC (US) 2025-12-04 US disclosed
EP-4655423-A1 INFERRING MICROORGANISM OF ORIGIN FOR ANTIMICROBIAL RESISTANCE MARKERS IN TARGETED METAGENOMICS Illumina, Inc. (US) 2025-12-03 EP disclosed
US-12467086-B2 Sequencing by structure assembly PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2025-11-11 US disclosed
US-20250277224-A1 COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES FLAGSHIP PIONEERING INNOVATIONS VI, LLC 2025-09-04 US disclosed
US-12378600-B2 Linkers and methods for optical detection and sequencing ULTIMA GENOMICS, INC. (US) 2025-08-05 US disclosed
US-12338474-B2 Compositions and methods for producing circular polyribonucleotides FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2025-06-24 US disclosed
US-20250188505-A1 PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A PROKARYOTIC SYSTEM FLAGSHIP PIONEERING INNOVATIONS VII LLC (US) 2025-06-12 US disclosed
WO-2025097012-A1 METHODS OF SORTING SPERM BASED ON GENOTYPE MAVEN BONNIE E J (US) 2025-05-08 WO disclosed
US-20250129419-A1 REAGENTS FOR LABELING BIOMOLECULES AND USES THEREOF ULTIMA GENOMICS INC (US) 2025-04-24 US disclosed
CN-114007614-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-02-01 CN disclosed
CN-114007613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-02-01 CN disclosed
CN-114007612-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-02-01 CN disclosed
CN-114007611-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-02-01 CN disclosed
US-20180340020-A1 PEPTIDE-MEDIATED DELIVERY OF IMMUNOGLOBULINS ACROSS THE BLOOD-BRAIN BARRIER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2018-11-29 US disclosed
US-10072065-B2 Peptide-mediated delivery of immunoglobulins across the blood-brain barrier MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2018-09-11 US disclosed
US-20170058017-A1 PEPTIDE-MEDIATED DELIVERY OF IMMUNOGLOBULINS ACROSS THE BLOOD-BRAIN BARRIER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2017-03-02 US disclosed
US-8715923-B2 Protein scaffolds and viral particles for detecting analytes THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2014-05-06 US disclosed
US-20080220408-A1 Non-enveloped virus particles comprising a plurality of detectable fluorescent labels for use in solid support for detecting preferential particles in solutions THE GOVERNMENT OF THE US, AS REPRESENTED BY THE SE (US) 2008-09-11 US disclosed
WO-2006124044-A2 PROTEIN SCAFFOLDS AND VIRAL PARTICLES FOR DETECTING ANALYTES GEORGE MASON UNIVERSITY (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028671-A1 Sequencing by Structure Assembly POLL, CPSF7, POLM EP300 4879/4885FAAH 1883/4885SOAT1 3802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.